Jonathan Allan Sells 2,266 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,266 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $19,646.22. Following the completion of the transaction, the general counsel now owns 33,510 shares in the company, valued at approximately $290,531.70. This trade represents a 6.33 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Stoke Therapeutics Stock Down 2.2 %

STOK opened at $8.15 on Friday. The company’s 50-day moving average price is $9.47 and its 200 day moving average price is $11.42. Stoke Therapeutics, Inc. has a fifty-two week low of $6.29 and a fifty-two week high of $17.58. The firm has a market cap of $431.68 million, a price-to-earnings ratio of -3.88 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of STOK. KLP Kapitalforvaltning AS bought a new stake in Stoke Therapeutics in the 4th quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new position in shares of Stoke Therapeutics during the fourth quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. bought a new position in Stoke Therapeutics in the 4th quarter worth approximately $124,000. Tower Research Capital LLC TRC increased its position in Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after acquiring an additional 4,918 shares during the period. Finally, Invesco Ltd. bought a new stake in Stoke Therapeutics during the 4th quarter valued at $133,000.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on STOK shares. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.